BNR
Burning Rock·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
BNR Profile
Burning Rock Biotech Limited
A China based company that provides next generation sequencing based cancer therapy for precision oncology
Biological Technology
03/10/2014
06/12/2020
NASDAQ Stock Exchange
674
12-31
Depository Receipts (Ordinary Shares)
No. 5, Xingdao Ring Road North, International Bio Island, Guangzhou, 510005, The People’s Republic of China
Oncology Precision Medicine Provides Second-Generation Sequencing Services with Clinical Value
Burning Rock Medicine LLC was incorporated in the Cayman Islands on March 10, 2014, focusing on providing next generation sequencing (NGS) services with clinical value for oncology precision medicine, The company's business and R&D directions mainly cover: (1) precision medical detection of cancer patients; (2) biomarker and companion diagnostic cooperation of global anti-tumor drug companies; and (3) early detection of multiple cancer types based on liquid biopsy. Burning Rock Medicine was awarded the first certificate of China's tumor NGS detection kit issued by the National Medical Products Administration (NMPA) in July 2018, which is a milestone in the field of in vitro diagnosis. The laboratory has obtained the technical audit of the "High-throughput Sequencing Laboratory" issued by the Guangdong Provincial Interim Inspection Center, as well as the American CLIA and CAP laboratory quality system qualification certification. The company will continue to devote itself to the development of innovative and reliable NGS detection products to promote the development of tumor precision medicine.
